MaxCyte (NASDAQ:MXCT – Get Free Report) and Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, risk, earnings and analyst recommendations.
Profitability
This table compares MaxCyte and Nautilus Biotechnology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MaxCyte | -114.77% | -18.92% | -16.14% |
| Nautilus Biotechnology | N/A | -37.58% | -30.83% |
Insider and Institutional Ownership
68.8% of MaxCyte shares are owned by institutional investors. Comparatively, 50.7% of Nautilus Biotechnology shares are owned by institutional investors. 4.1% of MaxCyte shares are owned by insiders. Comparatively, 41.1% of Nautilus Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MaxCyte | 1 | 1 | 1 | 0 | 2.00 |
| Nautilus Biotechnology | 1 | 0 | 1 | 0 | 2.00 |
MaxCyte presently has a consensus target price of $5.00, indicating a potential upside of 290.62%. Nautilus Biotechnology has a consensus target price of $4.00, indicating a potential upside of 342.04%. Given Nautilus Biotechnology’s higher possible upside, analysts plainly believe Nautilus Biotechnology is more favorable than MaxCyte.
Valuation and Earnings
This table compares MaxCyte and Nautilus Biotechnology”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MaxCyte | $33.03 million | 4.00 | -$44.63 million | ($0.33) | -3.88 |
| Nautilus Biotechnology | N/A | N/A | -$59.00 million | ($0.45) | -2.01 |
MaxCyte has higher revenue and earnings than Nautilus Biotechnology. MaxCyte is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
MaxCyte has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Nautilus Biotechnology has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500.
Summary
MaxCyte beats Nautilus Biotechnology on 7 of the 11 factors compared between the two stocks.
About MaxCyte
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
About Nautilus Biotechnology
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. It also offers proteome analysis system, a high-resolution optical imaging system for integrated fluidics and liquid handling sub-system. In addition, the company provides sample preparation, flow cells, multi-affinity probe reagents, and instrument buffers system to perform multi-cycle analysis runs. Nautilus Biotechnology, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Receive News & Ratings for MaxCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MaxCyte and related companies with MarketBeat.com's FREE daily email newsletter.
